Xiujian Wang
Overview
Explore the profile of Xiujian Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Tao X, Chen P, Jiang P, Li W, Chang H, et al.
Signal Transduct Target Ther
. 2024 Oct;
9(1):293.
PMID: 39438476
Clinical evidence supports the notion that T cell exhaustion and terminal differentiation pose challenges to the persistence and effectiveness of chimeric antigen receptor-T (CAR-T) cells. MEK1/2 inhibitors (MEKIs), widely used...
2.
Zhu M, Han Y, Gu T, Wang R, Si X, Kong D, et al.
Cell Rep
. 2024 Apr;
43(4):114065.
PMID: 38578828
Epigenetic modification shapes differentiation trajectory and regulates the exhaustion state of chimeric antigen receptor T (CAR-T) cells. Limited efficacy induced by terminal exhaustion closely ties with intrinsic transcriptional regulation. However,...
3.
Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, et al.
Cell Rep Med
. 2024 Feb;
5(2):101400.
PMID: 38307031
Chimeric antigen receptor (CAR)-T therapy has shown superior efficacy against hematopoietic malignancies. However, many patients failed to achieve sustainable tumor control partially due to CAR-T cell exhaustion and limited persistence....
4.
Si X, Shao M, Teng X, Huang Y, Meng Y, Wu L, et al.
Cell Metab
. 2024 Jan;
36(1):176-192.e10.
PMID: 38171332
The efficacy of chimeric antigen receptor (CAR) T cell therapy is hampered by relapse in hematologic malignancies and by hyporesponsiveness in solid tumors. Long-lived memory CAR T cells are critical...
5.
Shao M, Teng X, Guo X, Zhang H, Huang Y, Cui J, et al.
Adv Sci (Weinh)
. 2022 Jan;
9(9):e2103508.
PMID: 35032108
Chimeric antigen receptor (CAR) T cells are potent agents for recognizing and eliminating tumors, and have achieved remarkable success in the treatment of patients with refractory leukemia and lymphoma. However,...
6.
Zhao H, Li X, Wang X, Meng M, Wang X, Huang S, et al.
Polymers (Basel)
. 2022 Jan;
14(1).
PMID: 35012117
The purpose of this work is to investigate the effects of copper (II) sulfate on the formaldehyde release and the mechanical properties of urea formaldehyde (UF) adhesive. Copper (II) sulfate...
7.
Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B, et al.
Cancer Immunol Res
. 2021 Jul;
9(9):1061-1070.
PMID: 34290048
Chimeric antigen receptor (CAR) T-cell therapies that target either CD19 or CD22 alone have potent antilymphoma effects. However, antigen escape-mediated relapse often occurs. CAR T cells targeting both CD19 and...
8.
Zhang H, Hu Y, Shao M, Teng X, Jiang P, Wang X, et al.
J Hematol Oncol
. 2021 Jul;
14(1):113.
PMID: 34289897
Relapses of CD19-expressing leukemia in patients who achieved initial remission after CART cell treatment have been reported to correlate with poor CART cells persistence. Sustained tonic signaling or strong activation...
9.
Wang X, Hu Y, Liu X, Yu J, Xu P, Wei G, et al.
Bone Marrow Transplant
. 2019 Aug;
54(12):2072-2080.
PMID: 31383996
Chimeric antigen receptor (CAR) T-cell therapy has displayed potent anti-leukemia activity in acute lymphocytic leukemia (ALL), acting as a new ray of hope to refractory/relapsed patients. However, the influence of...
10.
Zhu J, Xu C, Wang X, Shi W
Pak J Pharm Sci
. 2018 Nov;
31(5(Special)):2191-2195.
PMID: 30463811
At present, the drugs used in the field of postoperative analgesia are mainly opioids. The three analgesics selected in this study are opioid receptor agonists, but opioids are easy to...